Because of the previous data suggesting activity of IFNs in recurrent GBM, we undertook the studies reported here to determine whether IFNα2b (standard and pegylated formulation) along with TMZ at the standard 5-day dosing scheme could improve 6-month progression-free survival (PFS-6) in patients with recurrent GBM. This evidence concerns the gene IFNA2 and glioblastoma.